This study aims to evaluate the clinical efficacy of cyclophosphamide in patients receiving a bone marrow graft from a matched unrelated donor in overall survival, progression free survival and cumulative incidence of acute and chronic GvHD. Thirty patients will receive cyclophosphamide while twenty patients will receive antihuman T-lymphocyte immune globulin (ATG).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Enrollment
50
Cyclophosphamide 1000 mg/flask
Antihuman T-Lymphocyte Immune Globulin 25 mg/flask
Hospita Israelita Albert Eintein
São Paulo, São Paulo, Brazil
RECRUITINGOverall Survival
Time to last follow-up or death
Time frame: 4 years
Progression free survival
Time until last follow-up, death or disease relapse
Time frame: 4 years
Acute Graft Versus Host Disease
Time until acute GvHD development
Time frame: 4 years
Chronic Graft Versus Host Disease
Time until chronic GvHD development
Time frame: 4 years
Treatment Related Mortality
Time until death related to HSCT complications
Time frame: 4 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.